P2X7 antagonist programme, EVT 401, to a top tier global animal health company partnered
Exclusive license granted to major animal health company for development of Evotec proprietary compound
Evotec AG announced that it has entered into a world-wide license and collaboration agreement with a top tier animal health company that intends to develop the proprietary Evotec compound EVT401, a selective, small molecule P2X7 antagonist, in the companion animal market.
Evotec is entitled to receive a technology- transfer payment, development and commercial milestone payments, and tiered royalties on net sales. Evotec retains all rights to the programme for human therapeutic use.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are very pleased to be partnering with a company that has proven capabilities for developing drug candidates for animal indications. This deal not only gives us additional product value, but also nicely proves the strength of our medicinal chemistry approach. We look forward to closely collaborate with this top animal health company to make this product development a success."
Financial details related to the agreement are not being disclosed.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.